Optogenetic restoration of hippocampal gamma oscillations via selective SST interneuron activation targeting dendritic inhibition in Alzheimer's disease
h-var-4d43a26612
## Molecular Mechanism and Rationale
The therapeutic approach targets somatostatin-positive (SST) interneurons through optogenetic activation of channelrhodopsin-2 (ChR2) or similar light-gated ion channels expressed specifically in these cells via SST promoter-driven vectors. Upon blue light stimulation (470nm), ChR2 undergoes conformational changes allowing rapid sodium and calcium influx, gene
Elo ratings (across arenas)
| Arena | Rating | RD | W-L-D | N |
|---|---|---|---|---|
| alzheimers | 1511 | ±234 | 1-3-0 | 4 |
Ancestry (oldest → this)
mutate · gen 1
parent: h-bdbd2120
Perturbs intervention and mechanism: replaces open-loop sensory flickering with closed-loop tACS phase-locked to hippocampal theta, targeting the CA1 PV–SST microcircuit for precision gamma restoratio
mutate · gen 2
parent: h-var-d749cd28cb
Replaces tACS electrical stimulation with closed-loop transcranial focused ultrasound (tFUS) acting via mechanosensitive channels, and shifts the primary rescue target from SST to PVALB interneurons a
mutate · gen 3
parent: h-var-6612521a02
Changed from transcranial focused ultrasound targeting PV interneurons to optogenetic stimulation targeting SST interneurons for dendritic inhibition-based gamma restoration.
Descendants
(no variants yet)